Home › Health › Chinese drug iza-bren doubles lung cancer survival...
Health

Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial

Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial
Key Points

An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid last week. Researchers said the drug, iza-bren, showed a significant advantage over platinum-based chemotherapy in a phase 3 randomised, double-blind clinical trial conducted at 73 hospitals in China and involving 432 patients with advanced lung cancer. The median progression-free survival (PFS) – the...

An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid last week. Researchers said the drug, iza-bren, showed a significant advantage over platinum-based chemotherapy in a phase 3 randomised, double-blind clinical trial conducted at 73 hospitals in China and involving 432 patients with advanced lung cancer. The median progression-free survival (PFS) – the length of... [Image text:] Isesntamab Erngitecat ler 2njectio HER Corsn 120mg 120 B.ECE IM SIKEL CSE
Chinese (ORG) iza-bren (PERSON) Sichuan Biokin Pharmaceutical (ORG) the European Society for Medical Oncology (ORG) ESMO (ORG) Congress (ORG) Madrid (LOCATION) China (LOCATION)
Originally published by South China Morning Post Read original →